Palvella reports positive bleeding results from QTORIN rapamycin trial

May 15, 2026 7:30 AM

Palvella Therapeutics Inc. (NASDAQ: PVLA) presented new data from its Phase 2 TOIVA trial of QTORIN rapamycin for treating cutaneous ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found